Obesity Drug Coverage Should Not Be Required For ACA Plans, Cigna Tells CMS
Executive Summary
Insurer's concerns about the cost of covering drugs that could be used by large swaths of the population has contributed to their reluctance to pay for them, but in comments to the agency, drug firms, consumer advocates and medical professionals urged the Centers for Medicare and Medicaid Services to promote coverage in the commercial plans governed by the Affordable Care Act.
You may also be interested in...
‘Essential’ Drug Coverage Including Obesity Treatments Make Sense For ACA Plans, CMS Says
But the Centers for Medicare and Medicaid Services wants to see data first on how promoting coverage of the new obesity drugs would impact uptake, plan costs and beneficiary premiums.
Wegovy’s Cardiovascular Benefits May Improve, But Not Transform, Insurance Coverage In Obesity
Novo Nordisk’s obesity drug lowered adverse cardiovascular events by an impressive 20% in a pivotal study. However, payers may still want data on how paying for obesity drugs could lower their overall medical expenses.
Obesity Drug Coverage In ACA Plans May Expand With Shift In Treatment Classification Standard
Current drug classification standard was originally designed for the Medicare Part D program, which does not cover obesity drugs.